Abstract: Methods and compositions relating to anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.
Type:
Application
Filed:
April 30, 2009
Publication date:
December 10, 2009
Applicants:
SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institute of Health, Office of Technology Transfer
Inventors:
David J. FitzGerald, Ira Pastan, Elizabeth Mansfield, Robert Kreitman
Abstract: Systems and methods are disclosed for directing magnetizable particles comprising therapeutic agents to a target volume, or for guiding magnetizable particles comprising therapeutic agents from a first target volume to a second target volume, at a distance using a magnetic field, to enable the treatment of diseased areas including areas deep inside a patient's body. The methods may be used to diagnose or treat diseased areas within a patient, for example tumors of the lungs, intestines, and liver, and is also useful in enhancing the permeability of solid tumors to chemotherapeutic agents.
Type:
Application
Filed:
May 19, 2009
Publication date:
November 19, 2009
Applicants:
UNIVERSITY OF MARYLAND, NATIONAL INSTITUTES OF HEALTH
Inventors:
Benjamin Shapiro, Michael R. Emmert-Buck
Abstract: The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.
Type:
Application
Filed:
October 23, 2007
Publication date:
November 12, 2009
Applicants:
The Regents of the University of California, of Health and Human Services National Institutes of Health Office of Technology Transfer
Inventors:
Charles S. Zuker, Jon E. Adler, Nick Ryba, Ken Mueller, Mark Hoon
Abstract: Computation-saving techniques and stability-adding techniques provide for fast, accurate reconstructions of a time series of images involving large-scale 3D problems, such as real-time image recovery in an optical tomography imaging system. A system equation for a target medium (116) such as tissue is solved using a Normalized Difference Method (NDM) (250). Because of the inherent stability of the NDM solutions, a weight matrix (W) of the system equation can be provided for a given point in a time series (220), then reused without recalculation at subsequent points. Further savings are achieved by decomposing W using singular value decomposition or direct matrix decomposition, transforming it to reduce its dimensions, and/or scaling it to achieve a more stable numerical solution. Values of measured energy (112) emerging from the target medium are back-substituted into the system equation for the different points to obtain the target medium properties.
Type:
Grant
Filed:
April 7, 2003
Date of Patent:
November 10, 2009
Assignees:
National Institutes of Health (NIH), The United States of America as represented by the Department of Health and Human Services
Abstract: Compounds represented by the formula: wherein R is C1-6 alkyl; C4-6 cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to ? agonists.
Type:
Application
Filed:
March 19, 2009
Publication date:
September 24, 2009
Applicants:
Southern Research Institute, National Institute on Drug Abuse, National Institute of Health, University of New England College of Osteopathic Medicine, The Arizona Board of Reagents on behalf of the University of Arizona
Inventors:
Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
Abstract: The invention relates to a novel protease, called SENP1, which is active against sentrin-modified proteins in vivo. The invention more specifically relates to the genomic and amino acid sequences for SENP1, compositions related to and based on these sequences, and methods of using these sequences and compositions.
Type:
Grant
Filed:
July 22, 2003
Date of Patent:
September 15, 2009
Assignees:
National Institutes of Health (NIH), The United States of America as represented by the Department of Health and Human Services, U.S. Government NIH Divisional of Extramural Inventions and Technology Resources (DEITR)
Abstract: The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased by the presence of the destabilizing amino acid sequence. The invention also relates to nucleic acids encoding secreted fusion proteins, such as those containing chemokines or cytokines, and an attached amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased as a result of being attached to the secretory sequence. The invention also relates methods of increasing the immunogenicity of the encoded proteins for use as vaccines or in gene therapy.
Type:
Application
Filed:
April 20, 2009
Publication date:
September 10, 2009
Applicants:
Department of Health and Human Services, National Institute of Health
Inventors:
George N. Pavlakis, Alexander Gragerov, Barbara K. Felber
Abstract: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.
Type:
Application
Filed:
February 16, 2007
Publication date:
August 20, 2009
Applicant:
National Institutes of Health Office of Technology
Inventors:
Gary J. Nabel, Wing-pui Kong, Zhi-yong Yang
Abstract: An eye examination device has a fundus observation system and an optical stimulation system. The optical stimulation system has an optical targeting subsystem and an optical stimulation subsystem, wherein the optical stimulation system is structured to be used to provide light stimulation to a portion of a fundus of an eye targeted by the optical targeting subsystem in conjunction with observations made with the fundus observation system.
Type:
Application
Filed:
July 28, 2008
Publication date:
August 13, 2009
Applicants:
Health and Human Services, National Institutes of Health
Inventors:
Paul D. Smith, Francisco De Monasterio, Edward Wellner
Abstract: A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety controls the biological activity of the effector moiety by interacting with the effector moiety. The oligonucleotide can assume a hairpin configuration, where the effector and regulating moieties interact, or an open configuration, where the effector and regulating moieties fail to interact. Depending on the nature of the effector and regulating moieties, either configuration can result in the expression of the biological activity of the effector moiety.
Type:
Application
Filed:
July 7, 2005
Publication date:
August 13, 2009
Applicant:
National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)
Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.
Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.
Type:
Application
Filed:
June 30, 2006
Publication date:
July 2, 2009
Applicant:
National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Gov.
Abstract: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.
Type:
Grant
Filed:
February 26, 2007
Date of Patent:
June 16, 2009
Assignees:
Nabi Biopharmaceuticals, United States of America as Represented by the Secretary, DHHS Office of Technology Transfer, National Institutes of Health
Inventors:
Sofiane Ennifar, Scott Winston, James Terrill, Steve Fuller
Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
Type:
Application
Filed:
January 21, 2009
Publication date:
May 21, 2009
Applicants:
TorreyPines Therapeutics, National Institutes of Health (NIH)
Inventors:
Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
Type:
Grant
Filed:
August 9, 2002
Date of Patent:
March 31, 2009
Assignee:
The National Institutes of Health
Inventors:
Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
Abstract: The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.
Type:
Grant
Filed:
August 20, 2003
Date of Patent:
March 24, 2009
Assignees:
The Regents of the University of California, United States of America Dept. of Health and Human Services National Institutes of Health-OTT
Inventors:
Charles S. Zuker, Nicholas J. P. Ryba, Gregory A. Nelson, Mark A. Hoon, Jayaram Chandrashekar, Yifeng Zhang
Abstract: Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-? on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-?.
Type:
Application
Filed:
August 19, 2008
Publication date:
March 19, 2009
Applicants:
University of Southern California, National Institutes of Health
Abstract: The invention provides adenovirus and retrovirus vectors useful to prepare influenza virus. Also provided is a canine RNA polymerase I promoter and vectors having that promoter.
Type:
Application
Filed:
June 13, 2008
Publication date:
February 19, 2009
Applicant:
National Institutes of Health (NIH) NIH division of Extramural Inventions and Technology Resources
Abstract: Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD.
Type:
Application
Filed:
August 20, 2007
Publication date:
November 13, 2008
Applicants:
University of Iowa Research Foundation, The Trustees of Columbia University in The City of New York, National Institutes of Health Office of Technology Transfer
Inventors:
Gregory S. Hageman, Rando Allikmets, Michael C. Dean, Albert M. Gold